Le Lézard
Classified in: Health, Business
Subject: JVN

Insilico Medicine and ChemDiv form a strategic drug discovery service alliance

SAN DIEGO, Oct. 16, 2019 /PRNewswire/ -- Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration combines the most advanced artificial intelligence (AI) techniques with a premium integrated drug discovery shared risk platform. The combination of complementary capabilities introduces a new value for companies working in the field, giving them a powerful tool for quick, cost-effective therapeutic product development.

ChemDiv logo

"We're pleased to partner with ChemDiv, the leading discovery contract research organization, which built a massive repository of small molecules," said Alex Zhavoronkov, PhD., CEO of Insilico Medicine. "ChemDiv has had a number of highly successful collaborations with pharmaceutical companies in multiple therapeutic areas, moving their discoveries from the unique chemistry idea into the clinic. Together we will improve the novelty, quality and efficiency of preclinical drug discovery and bring our technology and experience to other biotech and pharma partners."

Sergey Bugrov, Executive Director of ChemDiv commented, "With Insilico Medicine's AI technology previously intractable targets could become viable therapeutic opportunities and the time for preclinical drug discovery could dramatically shorten. Our joint goal is to generate new leads against identified and predicted novel targets. It allows us to continuously deliver great service to our partners and help them develop effective treatments for unmet medical needs."

The commercial terms will include technology access, success focused milestone and royalties.

About ChemDiv

ChemDiv is a recognized global leader in drug discovery solutions. Over the past 29 years ChemDiv has delivered hundreds of leads, drug candidates and new drugs in the area of CNS, oncology, virology, inflammation, cardiometabolic and immunology, to pharma, biotech and academic partners around the globe. [www.chemdiv.com]

About Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with offices in six countries and regions. The Company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas and anti-aging fields. Recently, Insilico Medicine published some of the resuts in Nature Biotechnology, and secured $37 million in series B funding. Website http://insilico.com/

Media Contacts

For further information, images or interviews, please contact:
Klug Gehilfe ai@pharma.ai

Please contact Ronald Demuth, rdemuth@chemdiv.com



These press releases may also interest you

at 15:05
Origin Gold Corporation ("Origin Gold" or the "Company") is pleased to announce that Deborah Battiston has been appointed as the chief financial officer and secretary of the Company and Jaime Lalinde has been appointed to the Company's board of...

at 15:00
Terry Duguid, Parliamentary Secretary to the Minister of Economic Development and Official Languages (Western Economic Diversification Canada), will deliver remarks at the IMPACT Sustainability Travel and Tourism Conference on behalf of the...

at 15:00
The "Big Data in E-commerce: Global Markets" report has been added to ResearchAndMarkets.com's offering. The Global Market for Big Data in E-Commerce Should Grow from $2.5 Billion in 2018 to $6.2 Billion by 2025, at a CAGR of 13.8% for the Period of...

at 14:52
On Monday T5 Data Centers, a leading provider of mission-critical development, facilities management and construction services, announced the purchase of a 164,000-square-foot data center shell in the Elk Grove Technology Park. The facility will...

at 14:30
METRO will hold its Annual General Meeting of Shareholders and announce its first quarter fiscal 2020 results. Event Information: Tuesday, January 28, 2020 ? 10 a.m.Centre Mont-Royal, Salon Mont-Royal2200 Mansfield Street, Montreal Journalists who...

at 14:28
The Brand is Female, one of Canada's top women empowerment podcasts has launched its latest season, sponsored by TD Bank Group. The podcast features weekly episodes where women leaders, including entrepreneurs, business leaders, media personalities...

News published on 16 october 2019 at 06:15 and distributed by: